Full Title: Optimizing Genomics Asset Management for High ROI - Evaluating Strategies to Support the Bio/Pharma
Value Chain
FREE BONUS REPORT(S): When you buy below report, you may pick 1 additional cancer report for free from this list
(Value: 2,468 USD)
Introduction The need to overcome the pharma industry’s pipeline productivity crisis is forcing the genomics innovators and their partners to reshape their portfolio management. New asset allocation strategies and valuation methodologies are needed to support the evolution to a new business model emphasizing investment in technological diversification. Scope - Insight into the dynamics of the genomics sector, as it diversifies to meet the challenge of the evolving bio/pharma supply chain
- Survival strategies for potential postgenomics drug developers and successful exit strategies for failed genomics businesses
- Novel portfolio management and option based asset valuation to support postgenomics drug developers, genomics licensees and innovators
Highlights The early wave of the genomics revolution witnessed a spectacular stock value decline. This was caused by the lack of transparency between the industry’s innovating, investing and licensing arms, and by a high degree of speculation related to unrealistic market generation targets and lack of understanding of the technological complexities. The new wave of innovation is focusing on gene functionalities, population genomics, chemo- and pharmacogenomics. Drug developers should continue integrating well-defined genomics assets into their supply chains, work to maximize successful target validation and optimize alliance networks to ensure asset co-evolution and diversification. Conventional discount flow-based asset valuation cannot describe the complexity of each genomics asset. Therefore, blending quantitative real option based and qualitative multifactorial asset analysis models can offer flexible long-term asset allocation and a number of capital growth opportunities hidden in genomics assets. Reasons to Purchase - Understand the dynamics behind the early genomics devaluation, and develop winning business survival and successful postgenomics exit strategies
- Gain insight into how the new wave of genomics diversification helps the bio/pharma supply chain to recover from its current productivity crisis
- Improve genomics project valuation by combining novel multidimensional asset analysis for less supply chain complexity, with real option based methods
Pages: 90 Table of Contents Download TOC in PDF
|
